{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:34:35Z","timestamp":1771054475554,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd000205.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T00:00:00Z","timestamp":1516406400000}}],"reference-count":87,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000205.pub3","type":"journal-article","created":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T05:21:10Z","timestamp":1516425670000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Benzodiazepines for antipsychotic-induced tardive dyskinesia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Hanna","family":"Bergman","sequence":"first","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paranthaman S","family":"Bhoopathi","sequence":"additional","affiliation":[{"name":"Royal Care Super Speciality Hospital; Department of Psychiatry; Neelambur Coimbatore Tamil Nadu India 641062"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Soares-Weiser","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Editorial Unit; St Albans House, 57 - 59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,20]]},"reference":[{"key":"10.1002\/14651858.CD000205.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1176\/ajp.138.2.189","article-title":"Clonazepam and phenobarbital in tardive dyskinesia","volume":"138","author":"Bobruff","year":"1981","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archpsyc.1988.01800310063008","article-title":"Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative symptoms of schizophrenia","volume":"45","author":"Csernanksy","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00004714-198804000-00028","article-title":"The effect of benzodiazepines on tardive dyskinesia symptoms","volume":"8","author":"Csernansky","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/106002808301700705","article-title":"Diazepam in tardive dyskinesia","volume":"17","author":"Weber","year":"1983","journal-title":"Drug Intelligence and Clinical Pharmacy"},{"issue":"1","key":"10.1002\/14651858.CD000205.pub3-BIB0005|cit5","first-page":"17","article-title":"Clonazepam therapy of tardive dyskinesia: a double-blind trial","volume":"12","author":"Xiang","year":"1997","journal-title":"West China Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD000205.pub3-BIB0006|cit6","first-page":"31","article-title":"Gabapentin reduces neuroleptic-induced tardive dyskinesia","volume":"10","author":"Ginsberg","year":"2003","journal-title":"Primary Psychiatry"},{"issue":"5778","key":"10.1002\/14651858.CD000205.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.4.5778.25","article-title":"Persistent phenothiazine dyskinesia treated with tetrabenazine","volume":"4","author":"Godwin-Austen","year":"1971","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD000205.pub3-BIB0008|cit8","first-page":"138","article-title":"Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome","volume":"9","author":"Jus","year":"1974","journal-title":"Internal Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0009|cit9","first-page":"287","article-title":"Clonazepam in neuroleptic-induced akathisia: efficacy and dose-response relationship","volume":"8","author":"Petit","year":"1994","journal-title":"Fundamental and Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD000205.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02244343","article-title":"Intravenous benztropine and propranolol challenges in tardive akathisia","volume":"113","author":"Sachdev","year":"1993","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD000205.pub3-BIB0011|cit11","first-page":"189","article-title":"Comparative study of two benzodiazepines (\"diazepam\" versus \"nitrazepam\") in the treatment of postneuroleptic tardive dyskinesia","volume":"24","author":"Sarbulescu","year":"1986","journal-title":"Revue Roumaine de Neurologie et de Psychiatrie"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD000205.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0361-9230(80)90111-2","article-title":"Treatment of tardive dyskinesia with diazepam: indirect evidence for the involvement of limbic, possibly GABA-ergic mechanisms","volume":"5","author":"Singh","year":"1980","journal-title":"Brain Research Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD000205.pub3-BIB0013|cit13","first-page":"729","article-title":"Diazepam-induced changes in tardive dyskinesia: suggestions for a new conceptual model","volume":"17","author":"Singh","year":"1982","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0361-9230(83)90188-0","article-title":"Sustained improvement in tardive dyskinesia with diazepam: indirect evidence for corticolimbic involvement","volume":"11","author":"Singh","year":"1983","journal-title":"Brain Research Bulletin"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","article-title":"Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy","volume":"147","author":"Thaker","year":"1990","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000205.pub3-BIB0016|cit16","first-page":"19","article-title":"The control study of clonazepam and artane in akathisia","volume":"6","author":"Wang","year":"2000","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD000205.pub3-BIB0017|cit17","first-page":"284","article-title":"Persistent tardive dyskinesia treated with clonazepam","volume":"11","author":"Wang","year":"2002","journal-title":"Chinese Journal of Pharmacoepidemiology"},{"issue":"4","key":"10.1002\/14651858.CD000205.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.jcp.0000132440.27854.44","article-title":"Naltrexone treatment of tardive dyskinesia in patients with schizophrenia","volume":"24","author":"Wonodi","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD000205.pub3-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub3","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Alabed","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD000205.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0021|cit21","volume-title":"Tardive Dyskinesia: a Task Force Report of the American Psychiatric Association","author":"American Psychiatric Association","year":"1992"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4088\/JCP.v69n1008","article-title":"Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study","volume":"69","author":"Ascher-Svanum","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0023|cit23","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-079035-7.50021-X","article-title":"The side-effects of antipsychotic drugs","volume-title":"Antipsychotic Drugs and their Side-Effects","volume":"I. CNS and neur","author":"Barnes","year":"1993"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1192\/bjp.154.4.523","article-title":"The course of tardive dyskinesia in patients on long-term neuroleptics","volume":"154","author":"Bergen","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000205.pub3-BIB0026|cit26","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radical in neuroleptic-induced movement disorders","volume":"570","author":"Cadet","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD000205.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0447.1988.tb05138.x","article-title":"Tardive dyskinesia","volume":"77","author":"Casey","year":"1988","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0029|cit29","article-title":"Tardive dyskinesia: pathophysiology","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Casey","year":"1994"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JCP.0b013e3181929f94","article-title":"Mortality rates among patients with schizophrenia and tardive dyskinesia","volume":"29","author":"Chong","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000205.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychotherapy and Psychosomatics"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive dyskinesia: therapeutic options for an increasingly common disorder","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Current Opinion in Psychiatry"},{"issue":"9085","key":"10.1002\/14651858.CD000205.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(05)63833-0","article-title":"Meta-analyses of randomised controlled trials","volume":"350","author":"Davey Smith","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0036|cit36","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town (South Africa) The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0037|cit37","first-page":"1885","article-title":"Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice","volume":"11","author":"Dell'Osso","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"6","key":"10.1002\/14651858.CD000205.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD000205.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archpsyc.1980.01780190089011","article-title":"Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens","volume":"37","author":"Donlon","year":"1980","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD000205.pub3-BIB0042|cit42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000458.pub2","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000205.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD000205.pub3-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub3","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Essali","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.56.6.805","article-title":"The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up","volume":"56","author":"Fernandez","year":"2001","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD000205.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0047|cit47","article-title":"The treatment of tardive dyskinesia","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Gardos","year":"1994"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0447.1988.tb05138.x","article-title":"Tardive dyskinesia","volume":"77","author":"Gerlach","year":"1988","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1192\/bjp.157.4.585","article-title":"Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication","volume":"157","author":"Glazer","year":"1990","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000205.pub3-BIB0050|cit50","first-page":"21","article-title":"Expected incidence of tardive dyskinesia associated with atypical antipsychotics","volume":"61","author":"Glazer","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000205.pub3-BIB0051|cit51","first-page":"15","article-title":"Review of incidence studies of tardive dyskinesia associated with typical antipsychotics","volume":"61","author":"Glazer","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/309347a0","article-title":"Association with persistent neuroleptic induced dyskinesia of regional changes in brain GABA synthesis","volume":"309","author":"Gunne","year":"1984","journal-title":"Nature"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0054|cit54","article-title":"Abnormal Involuntary Movement Scale","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0056|cit56","volume-title":"Cochrane handbook for Systematic Reviews of Interventions 4.2.5 (updated May 2005)","author":"Higgins","year":"2005"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0057|cit57","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated September 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000205.pub3-BIB0058|cit58","first-page":"38","article-title":"Pharmacological treatments of tardive dyskinesia in the 1980s","volume":"8","author":"Jeste","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"7303","key":"10.1002\/14651858.CD000205.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"J\u0171ni","year":"2001","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0060|cit60","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"11","key":"10.1002\/14651858.CD000205.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000205.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 29","key":"10.1002\/14651858.CD000205.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000298255","article-title":"Introduction","volume":"168","author":"Lieberman","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"15","key":"10.1002\/14651858.CD000205.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.285.15.1992","article-title":"Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0067|cit67","unstructured":"National Institute for Health and Care Excellence Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178 guidance.nice.org.uk\/cg178 2014"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0068|cit68","first-page":"28","article-title":"Benzodiazepine use, abuse, and dependence","volume":"66 Suppl 2","author":"O'Brien","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/gps.4399","article-title":"Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis","volume":"31","author":"O'Brien","year":"2016","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"3","key":"10.1002\/14651858.CD000205.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0072|cit72","first-page":"431","article-title":"The clinical research for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0073|cit73","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0074|cit74","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","author":"Shokraneh","journal-title":"BioImpacts"},{"issue":"2","key":"10.1002\/14651858.CD000205.pub3-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"1997","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000205.pub3-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000205.pub3-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000205.pub3-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"Soares-Weiser","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000205.pub3-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209.pub2","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD000205.pub3-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0081|cit81","doi-asserted-by":"crossref","DOI":"10.3109\/9780203092835","volume-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2009"},{"issue":"5","key":"10.1002\/14651858.CD000205.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"2","key":"10.1002\/14651858.CD000205.pub3-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Walker","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD000205.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD000205.pub3-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Bhoopathi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD000205.pub3-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205","article-title":"Neuroleptic-induced tardive dyskinesia: efficacy of benzodiazepines","author":"McGrath","year":"1996","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000205.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(99)00021-3","article-title":"The treatment of tardive dyskinesia: a systematic review and meta-analysis","volume":"39","author":"Soares-Weiser","year":"1999","journal-title":"Schizophrenia Research"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000205.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T03:13:27Z","timestamp":1660878807000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000205.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,20]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000205.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,20]]}}}